|
G |
Abhd11 |
abhydrolase domain containing 11 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of ABHD11 protein |
CTD |
PMID:31370342 |
|
NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398
|
|
G |
Actr1a |
actin related protein 1A |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of ACTR1A protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:245,237,821...245,256,618
Ensembl chr 1:245,237,826...245,256,495
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
increases expression |
ISO |
tanespimycin results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:19514085 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
multiple interactions increases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of AGR2 protein tanespimycin analog results in increased expression of AGR2 protein; tanespimycin results in increased expression of AGR2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin results in decreased expression of AHR protein] |
CTD |
PMID:37217010 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak9 |
adenylate kinase 9 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of AK9 protein |
CTD |
PMID:31370342 |
|
NCBI chr20:44,724,494...44,941,135
Ensembl chr20:44,724,496...44,941,136
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression affects expression |
ISO EXP |
Arsenic Trioxide promotes the reaction [tanespimycin results in decreased expression of AKT1 protein]; tanespimycin affects the reaction [Cannabidiol affects the expression of AKT1 protein]; tanespimycin promotes the reaction [Arsenic Trioxide results in decreased expression of AKT1 protein]; tanespimycin results in decreased expression of and results in decreased phosphorylation of AKT1 protein tanespimycin affects the expression of AKT1 protein |
CTD |
PMID:16923571 PMID:17157164 PMID:18566239 PMID:22810956 PMID:26504004 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
ALB protein binds to tanespimycin ALB protein inhibits the reaction [Copper results in increased oxidation of tanespimycin analog] |
CTD |
PMID:18393300 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of ALDH1A1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Alk |
ALK receptor tyrosine kinase |
decreases activity decreases expression |
ISO |
tanespimycin results in decreased activity of ALK protein mutant form tanespimycin results in decreased expression of ALK protein; tanespimycin results in decreased expression of ALK protein modified form |
CTD |
PMID:21030459 PMID:21502504 |
|
NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
ISO |
tanespimycin results in increased expression of ANXA1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions increases expression |
ISO |
Scorpion Venoms results in increased susceptibility to [tanespimycin results in increased expression of APAF1 protein] |
CTD |
PMID:19913524 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Ar |
androgen receptor |
decreases expression |
ISO |
tanespimycin results in decreased expression of AR protein |
CTD |
PMID:17010675 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of ATP5F1A protein |
CTD |
PMID:31370342 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
tanespimycin analog results in decreased expression of ATP5F1B protein |
CTD |
PMID:31370342 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
tanespimycin results in decreased expression of BCL2 protein |
CTD |
PMID:16923571 PMID:28673683 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
tanespimycin results in decreased expression of BCL2L1 protein |
CTD |
PMID:16923571 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
tanespimycin results in increased expression of BCL2L11 protein |
CTD |
PMID:24784839 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
increases expression decreases expression |
ISO EXP |
tanespimycin analog results in increased expression of BRAF protein tanespimycin results in decreased expression of BRAF protein |
CTD |
PMID:22810956 PMID:31370342 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
[tanespimycin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; Scorpion Venoms results in increased susceptibility to [tanespimycin results in increased activity of CASP3 protein]; tanespimycin results in increased cleavage of and results in increased activity of CASP3 protein SH-6 compound promotes the reaction [tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]]; tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein] tanespimycin results in increased cleavage of CASP3 protein |
CTD |
PMID:15993848 PMID:17157164 PMID:18194434 PMID:19913524 PMID:22810956 PMID:24189122 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage multiple interactions |
ISO |
tanespimycin results in increased cleavage of CASP8 protein [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein |
CTD |
PMID:17121904 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
[tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein tanespimycin results in increased cleavage of CASP9 protein |
CTD |
PMID:17121904 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
tanespimycin results in decreased expression of CCND1 protein [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein |
CTD |
PMID:17121904 PMID:17157164 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of CCT8 protein |
CTD |
PMID:31370342 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions decreases expression |
ISO EXP |
[tanespimycin co-treated with NQO1 protein] results in decreased expression of CDC25C protein tanespimycin results in decreased expression of CDC25C protein |
CTD |
PMID:21156818 PMID:22810956 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression affects expression |
ISO |
[tanespimycin co-treated with NQO1 protein] results in decreased expression of CDK1 protein; tanespimycin affects the reaction [Cannabidiol affects the expression of CDK1 protein] tanespimycin results in decreased expression of CDK1 protein tanespimycin affects the expression of CDK1 protein |
CTD |
PMID:21156818 PMID:24784839 PMID:26504004 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
tanespimycin results in decreased expression of CDK4 protein |
CTD |
PMID:17157164 PMID:28673683 PMID:34291863 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk8 |
cyclin-dependent kinase 8 |
decreases expression |
ISO |
tanespimycin results in decreased expression of CDK8 protein |
CTD |
PMID:17157164 |
|
NCBI chr12:8,737,198...8,805,026
Ensembl chr12:8,737,262...8,804,177
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
tanespimycin results in decreased expression of CEBPB protein |
CTD |
PMID:33609515 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
tanespimycin analog results in increased expression of CES1 protein |
CTD |
PMID:31370342 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chp2 |
calcineurin-like EF hand protein 2 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of CHP2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:176,757,945...176,772,443
Ensembl chr 1:176,757,876...176,772,139
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
multiple interactions |
ISO |
tanespimycin promotes the reaction [COMMD1 protein results in increased degradation of HIF1A protein] |
CTD |
PMID:19802386 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Csde1 |
cold shock domain containing E1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of CSDE1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 2:190,546,015...190,582,787
Ensembl chr 2:190,554,980...190,582,784
|
|
G |
Cttn |
cortactin |
multiple interactions increases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of CTTN protein tanespimycin analog results in increased expression of CTTN protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing |
ISO |
CYP3A5 protein affects the metabolism of tanespimycin |
CTD |
PMID:15718306 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of DARS1 protein |
CTD |
PMID:31370342 |
|
NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
increases expression |
ISO |
tanespimycin results in increased expression of DHRS2 protein |
CTD |
PMID:31370342 |
|
NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
|
|
G |
Ebf2 |
EBF transcription factor 2 |
increases expression |
ISO |
tanespimycin analog results in increased expression of EBF2 protein |
CTD |
PMID:31370342 |
|
NCBI chr15:41,435,509...41,634,403
Ensembl chr15:41,435,509...41,634,403
|
|
G |
Echdc3 |
enoyl CoA hydratase domain containing 3 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of ECHDC3 protein |
CTD |
PMID:31370342 |
|
NCBI chr17:72,070,697...72,093,519
Ensembl chr17:72,070,668...72,093,516
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions decreases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of EEF1G protein tanespimycin analog results in decreased expression of EEF1G protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
increases expression multiple interactions |
ISO |
tanespimycin analog results in increased expression of EEF2 protein; tanespimycin results in increased expression of EEF2 protein [tanespimycin co-treated with VER 155008] results in increased expression of EEF2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression multiple interactions |
ISO |
tanespimycin analog results in decreased expression of EGFR protein; tanespimycin results in decreased expression of EGFR protein tanespimycin results in increased degradation of and results in decreased expression of EGFR protein |
CTD |
PMID:16061882 PMID:17010675 PMID:22810956 PMID:31370342 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
decreases expression multiple interactions |
ISO |
tanespimycin results in decreased expression of EIF3I protein [tanespimycin co-treated with VER 155008] results in decreased expression of EIF3I protein |
CTD |
PMID:31370342 |
|
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of EIF4B protein |
CTD |
PMID:31370342 |
|
NCBI chr 7:133,206,637...133,228,436
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of EIF4H protein |
CTD |
PMID:31370342 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Eml5 |
EMAP like 5 |
multiple interactions increases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of EML5 protein tanespimycin analog results in increased expression of EML5 protein |
CTD |
PMID:31370342 |
|
NCBI chr 6:118,046,655...118,175,831
Ensembl chr 6:118,046,655...118,175,831
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
tanespimycin analog results in increased expression of ENO1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases expression |
ISO |
tanespimycin results in increased degradation of and results in decreased expression of ERBB2 protein tanespimycin results in decreased expression of ERBB2 protein |
CTD |
PMID:16061882 PMID:24784839 PMID:34291863 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Eri1 |
exoribonuclease 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of ERI1 protein |
CTD |
PMID:31370342 |
|
NCBI chr16:56,724,101...56,744,228
Ensembl chr16:56,724,115...56,744,226
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of ERP29 protein |
CTD |
PMID:31370342 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Farsb |
phenylalanyl-tRNA synthetase subunit beta |
multiple interactions increases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of FARSB protein tanespimycin analog results in increased expression of FARSB protein; tanespimycin results in increased expression of FARSB protein |
CTD |
PMID:31370342 |
|
NCBI chr 9:79,887,852...79,947,082
Ensembl chr 9:79,887,842...79,947,045
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of FGF1 protein |
CTD |
PMID:31370342 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
tanespimycin results in increased degradation of and results in decreased expression of FGFR3 protein |
CTD |
PMID:16061882 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases expression |
ISO |
tanespimycin results in decreased expression of FLT3 protein |
CTD |
PMID:17010675 |
|
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of FUBP1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 2:241,159,481...241,186,591
Ensembl chr 2:241,159,512...241,186,602
|
|
G |
Gcfc2 |
GC-rich sequence DNA-binding factor 2 |
increases expression |
ISO |
tanespimycin analog results in increased expression of GCFC2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 4:114,481,613...114,519,268
Ensembl chr 4:114,481,607...114,519,962
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of GLS protein |
CTD |
PMID:31370342 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
tanespimycin results in decreased expression of GSK3B protein modified form |
CTD |
PMID:20090934 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gtf2a2 |
general transcription factor 2A subunit 2 |
increases expression |
ISO |
tanespimycin analog results in increased expression of GTF2A2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 8:70,662,447...70,675,576
Ensembl chr 8:70,662,428...70,675,569
|
|
G |
Gtf2ird1 |
GTF2I repeat domain containing 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of GTF2IRD1 protein |
CTD |
PMID:31370342 |
|
NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
tanespimycin promotes the reaction [COMMD1 protein results in increased degradation of HIF1A protein] |
CTD |
PMID:19802386 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of HINT1 protein |
CTD |
PMID:31370342 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
decreases expression multiple interactions |
ISO |
tanespimycin analog results in decreased expression of HSD17B10 protein; tanespimycin results in decreased expression of HSD17B10 protein [tanespimycin co-treated with VER 155008] results in decreased expression of HSD17B10 protein |
CTD |
PMID:31370342 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
affects localization multiple interactions increases activity |
ISO |
tanespimycin affects the localization of HSF1 protein [tanespimycin affects the localization of HSF1 protein] which results in increased expression of HSPA1A protein tanespimycin results in increased activity of HSF1 protein |
CTD |
PMID:20090934 PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions decreases expression affects binding |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of HSP90AA1 protein; N-(5-methylisoxazol-3-yl)-2-(4-(thiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-ylthio)acetamide inhibits the reaction [tanespimycin binds to HSP90AA1 protein] tanespimycin results in decreased expression of HSP90AA1 protein |
CTD |
PMID:18830594 PMID:22895790 PMID:31370342 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
affects binding |
ISO |
tanespimycin binds to HSP90AB1 protein |
CTD |
PMID:22895790 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions increases expression |
ISO |
[tanespimycin affects the localization of HSF1 protein] which results in increased expression of HSPA1A protein tanespimycin analog results in increased expression of HSPA1A protein |
CTD |
PMID:20090934 PMID:31370342 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of HSPA1B protein |
CTD |
PMID:31370342 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression multiple interactions |
ISO |
tanespimycin results in increased expression of HSPA4 protein [tanespimycin results in increased expression of HSPA4 protein] which results in decreased susceptibility to Doxorubicin |
CTD |
PMID:16311509 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
tanespimycin results in increased expression of HSPA5 protein |
CTD |
PMID:16357177 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of HSPA6 protein |
CTD |
PMID:31370342 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression multiple interactions |
ISO |
tanespimycin results in decreased expression of HSPD1 protein [tanespimycin co-treated with VER 155008] results in decreased expression of HSPD1 protein |
CTD |
PMID:23144451 PMID:31370342 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects expression decreases expression |
ISO EXP |
tanespimycin affects the expression of IGF1R protein tanespimycin results in decreased expression of IGF1R protein |
CTD |
PMID:22810956 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of ILF3 protein |
CTD |
PMID:31370342 |
|
NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350
|
|
G |
Kcnv2 |
potassium voltage-gated channel modifier subfamily V member 2 |
decreases expression multiple interactions |
ISO |
tanespimycin analog results in decreased expression of KCNV2 protein [tanespimycin co-treated with VER 155008] results in decreased expression of KCNV2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:224,999,552...225,014,062
Ensembl chr 1:224,999,552...225,014,062
|
|
G |
Kdm3a |
lysine demethylase 3A |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of KDM3A protein |
CTD |
PMID:31370342 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Kdr |
kinase insert domain receptor |
affects expression decreases expression |
ISO EXP |
tanespimycin affects the expression of KDR protein tanespimycin results in decreased expression of KDR protein |
CTD |
PMID:22810956 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression multiple interactions |
ISO EXP |
tanespimycin results in decreased expression of KIT protein tanespimycin results in increased degradation of and results in decreased expression of KIT protein |
CTD |
PMID:16061882 PMID:16213582 PMID:22810956 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Larp7 |
La ribonucleoprotein 7, transcriptional regulator |
increases expression |
ISO |
tanespimycin analog results in increased expression of LARP7 protein |
CTD |
PMID:31370342 |
|
NCBI chr 2:215,997,641...216,012,833
Ensembl chr 2:215,997,649...216,012,865
|
|
G |
Lcp1 |
lymphocyte cytosolic protein 1 |
increases expression multiple interactions |
ISO |
tanespimycin analog results in increased expression of LCP1 protein [tanespimycin co-treated with VER 155008] results in increased expression of LCP1 protein |
CTD |
PMID:31370342 |
|
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of LDHA protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
increases expression |
ISO |
tanespimycin analog results in increased expression of LDHB protein |
CTD |
PMID:31370342 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lmna |
lamin A/C |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of LMNA protein |
CTD |
PMID:31370342 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lrpprc |
leucine-rich pentatricopeptide repeat containing |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of LRPPRC protein |
CTD |
PMID:31370342 |
|
NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA]; [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein] |
CTD |
PMID:30796972 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions affects expression |
ISO EXP |
tanespimycin results in decreased phosphorylation of MAPK1 protein tanespimycin results in increased expression of and results in decreased phosphorylation of MAPK1 protein tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK1 protein] tanespimycin affects the expression of MAPK1 protein |
CTD |
PMID:17157164 PMID:20090934 PMID:21502504 PMID:22810956 PMID:24784839 PMID:26504004 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions affects expression |
ISO EXP |
tanespimycin results in decreased phosphorylation of MAPK3 protein tanespimycin results in increased expression of and results in decreased phosphorylation of MAPK3 protein tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK3 protein] tanespimycin affects the expression of MAPK3 protein |
CTD |
PMID:17157164 PMID:20090934 PMID:21502504 PMID:22810956 PMID:24784839 PMID:26504004 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
tanespimycin results in decreased expression of MCL1 protein |
CTD |
PMID:16923571 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases degradation |
ISO |
tanespimycin results in increased degradation of MDM2 protein |
CTD |
PMID:17157164 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
decreases expression |
EXP ISO |
tanespimycin results in decreased expression of MET protein |
CTD |
PMID:22810956 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions decreases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of MIF protein tanespimycin results in decreased expression of MIF protein |
CTD |
PMID:31370342 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mllt10 |
MLLT10, histone lysine methyltransferase DOT1L cofactor |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of MLLT10 protein |
CTD |
PMID:31370342 |
|
NCBI chr17:80,821,870...80,949,349
Ensembl chr17:80,822,556...80,949,345
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
tanespimycin affects the reaction [Nickel results in increased activity of MMP2 protein]; tanespimycin inhibits the reaction [Nickel results in increased expression of MMP2 mRNA] |
CTD |
PMID:21401309 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
tanespimycin affects the reaction [Nickel results in increased activity of MMP9 protein]; tanespimycin inhibits the reaction [Nickel results in increased expression of MMP9 mRNA] |
CTD |
PMID:21401309 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msn |
moesin |
increases expression |
ISO |
tanespimycin analog results in increased expression of MSN protein |
CTD |
PMID:31370342 |
|
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
|
|
G |
Mtap |
methylthioadenosine phosphorylase |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of MTAP protein |
CTD |
PMID:31370342 |
|
NCBI chr 5:103,874,460...103,920,684
Ensembl chr 5:103,873,020...103,939,406
|
|
G |
Mtss1 |
MTSS I-BAR domain containing 1 |
increases expression |
ISO |
tanespimycin results in increased expression of MTSS1 mRNA |
CTD |
PMID:19514085 |
|
NCBI chr 7:90,488,751...90,628,007
Ensembl chr 7:90,488,754...90,627,968
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of NAMPT protein |
CTD |
PMID:31370342 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nans |
N-acetylneuraminate synthase |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of NANS protein |
CTD |
PMID:31370342 |
|
NCBI chr 5:60,780,441...60,797,583
Ensembl chr 5:60,780,392...60,814,950
|
|
G |
Ncl |
nucleolin |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of NCL protein |
CTD |
PMID:31370342 |
|
NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression decreases phosphorylation |
EXP ISO |
tanespimycin results in increased expression of NFKBIA protein tanespimycin results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:11835313 PMID:22810956 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP |
Quercetin inhibits the reaction [tanespimycin results in decreased expression of NOS2 mRNA] |
CTD |
PMID:11835313 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases abundance increases reduction increases response to substance |
ISO |
[5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione results in decreased activity of NQO1 protein] which results in decreased abundance of tanespimycin; [5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione results in decreased activity of NQO1 protein] which results in decreased abundance of tanespimycin metabolite; [5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione results in decreased activity of NQO1 protein] which results in decreased susceptibility to tanespimycin; [NQO1 protein results in increased reduction of tanespimycin] which results in increased chemical synthesis of tanespimycin metabolite; [tanespimycin co-treated with NQO1 protein] results in decreased expression of CDC25C protein; [tanespimycin co-treated with NQO1 protein] results in decreased expression of CDK1 protein NQO1 protein results in increased abundance of tanespimycin; NQO1 protein results in increased abundance of tanespimycin metabolite NQO1 protein results in increased susceptibility to tanespimycin |
CTD |
PMID:10564678 PMID:21156818 PMID:24552538 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of OAT protein |
CTD |
PMID:31370342 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions increases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of PA2G4 protein tanespimycin analog results in increased expression of PA2G4 protein; tanespimycin results in increased expression of PA2G4 protein |
CTD |
PMID:31370342 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
EXP ISO |
tanespimycin results in increased cleavage of PARP1 protein |
CTD |
PMID:22810956 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
increases expression |
ISO |
tanespimycin analog results in increased expression of PARP2 protein |
CTD |
PMID:31370342 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
ISO EXP |
tanespimycin results in decreased expression of PDGFRB protein |
CTD |
PMID:22810956 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of PDIA4 protein |
CTD |
PMID:31370342 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
tanespimycin analog results in increased expression of PFN1 protein |
CTD |
PMID:31370342 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgr |
progesterone receptor |
decreases expression |
ISO |
tanespimycin results in decreased expression of PGR protein |
CTD |
PMID:11448926 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pip4k2c |
phosphatidylinositol-5-phosphate 4-kinase type 2 gamma |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of PIP4K2C protein |
CTD |
PMID:31370342 |
|
NCBI chr 7:63,020,004...63,035,086
Ensembl chr 7:63,020,000...63,035,078
|
|
G |
Pkm |
pyruvate kinase M1/2 |
decreases expression |
ISO |
tanespimycin results in decreased expression of PKM protein |
CTD |
PMID:31370342 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pnn |
pinin, desmosome associated protein |
increases expression |
ISO |
tanespimycin results in increased expression of PNN mRNA |
CTD |
PMID:19514085 |
|
NCBI chr 6:76,758,138...76,766,451
Ensembl chr 6:76,758,117...76,766,889
|
|
G |
Prkrip1 |
PRKR interacting protein 1 |
increases expression |
ISO |
tanespimycin analog results in increased expression of PRKRIP1 protein |
CTD |
PMID:31370342 |
|
NCBI chr12:20,470,802...20,491,789
Ensembl chr12:20,470,820...20,489,115
|
|
G |
Prps2 |
phosphoribosyl pyrophosphate synthetase 2 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of PRPS2 protein |
CTD |
PMID:31370342 |
|
NCBI chr X:26,975,915...27,013,184
Ensembl chr X:26,976,061...27,013,181
|
|
G |
Psma6 |
proteasome 20S subunit alpha 6 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of PSMA6 protein |
CTD |
PMID:31370342 |
|
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
|
|
G |
Psma7 |
proteasome 20S subunit alpha 7 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of PSMA7 protein |
CTD |
PMID:31370342 |
|
NCBI chr 3:167,137,279...167,143,626
Ensembl chr 3:167,137,263...167,143,672
|
|
G |
Rab17 |
RAB17, member RAS oncogene family |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of RAB17 protein |
CTD |
PMID:31370342 |
|
NCBI chr 9:91,552,924...91,566,759
Ensembl chr 9:91,553,464...91,566,451
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
tanespimycin results in decreased expression of RAF1 protein |
CTD |
PMID:10564678 PMID:34291863 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions |
ISO |
tanespimycin results in decreased phosphorylation of RB1 protein [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein |
CTD |
PMID:17121904 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rdx |
radixin |
increases expression multiple interactions |
ISO |
tanespimycin analog results in increased expression of RDX protein [tanespimycin co-treated with VER 155008] results in increased expression of RDX protein |
CTD |
PMID:31370342 |
|
NCBI chr 8:52,379,494...52,437,673
Ensembl chr 8:52,379,494...52,437,678
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of RPLP0 protein |
CTD |
PMID:31370342 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation decreases expression |
ISO |
tanespimycin results in decreased phosphorylation of RPS6 protein tanespimycin results in decreased expression of RPS6 protein |
CTD |
PMID:17121904 PMID:27255535 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
decreases expression |
ISO |
tanespimycin results in decreased expression of RUNX1 protein mutant form |
CTD |
PMID:33609515 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx1t1 |
RUNX1 partner transcriptional co-repressor 1 |
decreases expression |
ISO |
tanespimycin results in decreased expression of RUNX1T1 protein mutant form |
CTD |
PMID:33609515 |
|
NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592
|
|
G |
Selenbp1 |
selenium binding protein 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of SELENBP1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
|
|
G |
Serpinb5 |
serpin family B member 5 |
increases expression |
ISO |
tanespimycin results in increased expression of SERPINB5 mRNA |
CTD |
PMID:19514085 |
|
NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756
|
|
G |
Shmt2 |
serine hydroxymethyltransferase 2 |
decreases expression |
ISO |
tanespimycin analog results in decreased expression of SHMT2 protein |
CTD |
PMID:31370342 |
|
NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases abundance increases response to substance |
ISO |
SOD2 protein results in increased abundance of tanespimycin metabolite SOD2 protein results in increased susceptibility to tanespimycin |
CTD |
PMID:21156818 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srcin1 |
SRC kinase signaling inhibitor 1 |
increases expression multiple interactions |
ISO |
tanespimycin analog results in increased expression of SRCIN1 protein; tanespimycin results in increased expression of SRCIN1 protein [tanespimycin co-treated with VER 155008] results in increased expression of SRCIN1 protein |
CTD |
PMID:31370342 |
|
NCBI chr10:82,502,911...82,569,882
Ensembl chr10:82,504,393...82,571,040
|
|
G |
Tagln2 |
transgelin 2 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of TAGLN2 protein |
CTD |
PMID:31370342 |
|
NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
increases expression |
ISO |
tanespimycin results in increased expression of TIMP3 mRNA |
CTD |
PMID:19514085 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[tanespimycin co-treated with TNFSF10 protein] results in decreased expression of XIAP protein; [tanespimycin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein |
CTD |
PMID:15993848 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
tanespimycin results in decreased expression of TP53 protein |
CTD |
PMID:10564678 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpte2 |
transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 |
increases expression |
ISO |
tanespimycin analog results in increased expression of TPTE2 protein |
CTD |
PMID:31370342 |
|
NCBI chr16:69,658,874...69,756,571
Ensembl chr16:69,658,875...69,752,949
|
|
G |
Tymp |
thymidine phosphorylase |
decreases expression multiple interactions |
ISO |
tanespimycin results in decreased expression of TYMP mRNA; tanespimycin results in decreased expression of TYMP protein [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA]; [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein]; [tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA; acetylleucyl-leucyl-norleucinal inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]; SB 203580 promotes the reaction [[tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA]; tanespimycin inhibits the reaction [Dactinomycin promotes the reaction [salinomycin results in increased expression of TYMP mRNA]]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]]; tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP mRNA]; tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein] |
CTD |
PMID:30796972 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression |
ISO |
tanespimycin results in decreased expression of TYMS protein |
CTD |
PMID:18830594 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
increases expression |
ISO |
tanespimycin analog results in increased expression of UGDH protein; tanespimycin results in increased expression of UGDH protein |
CTD |
PMID:31370342 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
decreases expression |
ISO |
tanespimycin results in decreased expression of UGP2 protein |
CTD |
PMID:31370342 |
|
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
|
|
G |
Vil1 |
villin 1 |
increases expression |
ISO |
tanespimycin analog results in increased expression of VIL1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[tanespimycin co-treated with TNFSF10 protein] results in decreased expression of XIAP protein |
CTD |
PMID:15993848 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[tanespimycin co-treated with VER 155008] results in decreased expression of YARS1 protein |
CTD |
PMID:31370342 |
|
NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833
|
|
G |
Zyg11b |
zyg-11 family member B, cell cycle regulator |
multiple interactions increases expression |
ISO |
[tanespimycin co-treated with VER 155008] results in increased expression of ZYG11B protein tanespimycin analog results in increased expression of ZYG11B protein |
CTD |
PMID:31370342 |
|
NCBI chr 5:122,985,548...123,042,735
Ensembl chr 5:122,992,147...123,042,736
|
|